Retatrutide, an investigational triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, has shown considerable promise in promoting weight loss. Clinical trials have reported significant reductions in body weight for individuals receiving the drug. One Phase 2 study, conducted over 48 weeks, found that participants receiving the 12 mg dose experienced an average weight loss of approximately 24%, while those on the 8 mg dose lost about 22.8% of their body weight (pmc.ncbi.nlm.nih.gov, 2023).

Furthermore, a meta-analysis published in December 2024 evaluated the effects of subcutaneous retatrutide on patients with overweight, obesity, and type 2 diabetes. The results demonstrated a significant reduction in body weight and notable improvements in metabolic markers (pmc.ncbi.nlm.nih.gov, 2024).

While the benefits of retatrutide are clear, some patients may experience gastrointestinal side effects such as nausea and vomiting. These side effects are generally transient and tend to decrease over time. Ongoing research continues to evaluate the long-term safety and efficacy of retatrutide, with a focus on assessing these adverse events (pmc.ncbi.nlm.nih.gov, 2023).

References

National Center for Biotechnology Information. (2023). Retatrutide and its effects on weight loss in obese individuals. PubMed Central. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275

National Center for Biotechnology Information. (2024). Meta-analysis of retatrutide’s efficacy and metabolic markers in obesity and type 2 diabetes. PubMed Central. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11579655